Making Exercise Appealing for Young Couch Potatoes

Yes, there’s a television in Steinbeck’s Scottsdale, Ariz., home. But the family’s television room also boasts an exercise bicycle, mini trampoline, and several large exercise balls.

Her two children are just as interested in the tube as any other red-blooded American kids, but Steinbeck sees to it that if they’re tuned in, they’re exercising at the same time.

Everyone in the family uses the equipment as we watch television, the author of the best-selling Fat Free cookbook series explains. That way, the kids are hardly ever sitting and they’re in constant motion. It’s one way to make viewing more than a passive activity. Read more…

New fibrage-statin combos work their way through the system


The FDA is looking for more data to support a new US drug application for a product called Certriad which combines two cholesterol meds -- Abbott's TriLipix and AstraZeneca's Crestor.

TriLipix is a class of drugs called fibrages that boost "good" cholesterol and reduce triglycerides, a fat found in the blood stream, and "bad" cholesterol. Crestor is a statin that raises "good" HDL cholesterol while reducing "bad" HDL cholesterol.

The new product is intended to treat dyslipikemia, which results from elevated cholesterol and triglycerides. More than 100 million Americans suffer from the disorder says The American Heart Association.

The companies will continue to work with the FDA.

Studies on the effectiveness of statins in the prevention of cardiovascular disease are ongoing. One of many was reported in Journal Watch Cardiology last August by Dr Harlan Krumholz It results came from of an analysis of 10 trials with over 70,000 subjects over an average of 4 years, mean age 63, mean baseline LDL level 140, 2/3rds were male., ¼ of those had diabetes. Mortality was 5.7% in the control groups and 5.1% in the statin group. Go to http://bit.ly/bqbdnc for more.

The study concluded that statins can reduce the risk of cardiovascular events in those without cardiovascular disease.

1 comments:

said...

IF you don't have time to watch all of this excellent presentation on:

+ how HDL can become "bad."...

+how to properly test for it...

......**and the importance of "knowing" the IMPACT of medications that "raise good HDL"

then at least watch from 43:04 forward in the Q&A session**

http://www.youtube.com/watch?v=H_rPFF5X-pc

(Title: When Good Cholesterol Goes Bad )

In the clinical investigation between physician and client is there some danger in prescribing these medications without doing more advanced laboratory investigation of the existing nature of the the patient's HDL performance ( not just presence).
According to this researcher even APoA 1/HDL comparisons are not good enough.
Therefore the first step is to ensure the best laboratory assessment tool is in place first.